Navigation Links
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
Date:7/1/2009

EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease.

Under the terms of the agreement, Synageva will use its proprietary Synageva Expression Platform (SEP(TM)) technology and its expertise to produce and develop a therapeutic monoclonal antibody. SEP(TM) is an integrated platform of proprietary systems for protein production, processing and purification.

"Morphotek is an industry leader in antibody discovery and development," said Sanj K. Patel, President and Chief Executive Officer of Synageva BioPharma Corporation. "Their commitment to utilizing Synageva's platform is a testament to the strength of our science and product development capabilities and we are excited about the potential for this collaboration."

"We have a rich pipeline of antibody products such as MORAb-003, or farletuzumab, for ovarian cancer in Phase III, MORAb-009 for pancreatic cancer in Phase II and MORAb-004 that is pan-cancer specific in Phase I," stated Philip M. Sass, PhD, Executive Vice President and Chief Operating Officer, Morphotek, Inc. "We are always exploring new ways that may enhance the manufacturing process for our antibody products as a means to fulfill Eisai's hhc mission."

Through the use of its proprietary MORPHODOMA(R) technology, Morphotek develops optimized antibodies, including antibodies optimized for affinity and/or titer, for therapeutic applications and high-titer manufacturing cell lines. The company has assembled a portfolio of lead human and humanized antibodies to antigens associated with cancer, neovascular, inflammatory and infectious disease. The antibodies within the company's pipeline are targeted against a
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
2. Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
3. Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... zFlo Motion , a US leader in ... product from a new partner. STT-Systems has developed ... 15 years, with offerings in the optical-motion capture, 3D scanning, ... (inertial measurement unit), iSen, is opening eyes around the world. ...
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 23D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... Non-GAAP EPS Increased 22 Percent, CAMBRIDGE, Mass., April 23 ... the first quarter of,2008, which featured excellent revenue growth, continued ... the company., First-Quarter Highlights -- Total revenue ... $883.2 million in same period a ...
... Cardiac Science,Corporation (Nasdaq: CSCX ), a ... informatics products, announced today,that it will release its ... 2008 after the market close. The Company has ... 4:30 p.m. Eastern Time to,discuss the financial results ...
... image are better than one for analyzing tumors , ... determine the amount of oxygen in a tumor very useful, because ... a poor outcome. A new method to do this and to ... been developed and used to image tumors in mice by Murali ...
Cached Biology Technology:Genzyme Reports Strong First-Quarter Growth 2Genzyme Reports Strong First-Quarter Growth 3Genzyme Reports Strong First-Quarter Growth 4Genzyme Reports Strong First-Quarter Growth 5Genzyme Reports Strong First-Quarter Growth 6Genzyme Reports Strong First-Quarter Growth 7Genzyme Reports Strong First-Quarter Growth 8Genzyme Reports Strong First-Quarter Growth 9Genzyme Reports Strong First-Quarter Growth 10Genzyme Reports Strong First-Quarter Growth 11Genzyme Reports Strong First-Quarter Growth 12Genzyme Reports Strong First-Quarter Growth 13Genzyme Reports Strong First-Quarter Growth 14Genzyme Reports Strong First-Quarter Growth 15Genzyme Reports Strong First-Quarter Growth 16Genzyme Reports Strong First-Quarter Growth 17Genzyme Reports Strong First-Quarter Growth 18Genzyme Reports Strong First-Quarter Growth 19Cardiac Science Schedules First Quarter Earnings Release and Announces Conference Call 2JCI table of contents: April 22, 2008 2JCI table of contents: April 22, 2008 3JCI table of contents: April 22, 2008 4JCI table of contents: April 22, 2008 5JCI table of contents: April 22, 2008 6JCI table of contents: April 22, 2008 7JCI table of contents: April 22, 2008 8JCI table of contents: April 22, 2008 9JCI table of contents: April 22, 2008 10JCI table of contents: April 22, 2008 11JCI table of contents: April 22, 2008 12
(Date:1/22/2015)... Jan. 16, 2015  A man-made form of insulin delivered ... mental capabilities in adults with mild cognitive impairment and ... by researchers at Wake Forest Baptist Medical Center. ... amnesic mild cognitive impairment (MCI) or mild to moderate ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) ... Wearable Technologies Market and Applications, Opportunities, Industry Analysis, ... 2014-2020" report to their offering. , ... can be worn on the user,s body and ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... addition of the "The Global Watermarking and ... http://photos.prnewswire.com/prnh/20130307/600769 ... digital media watermarking and fingerprinting markets. Watermarking aims ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2
... first time, researchers have developed a way to synthesize a ... it works. , Derived from a fungus discovered clinging to ... certain cancer cells into suicide while leaving healthy cells untouched. ... might have some tremendous potential as a prototype anticancer agent, ...
... cell count" burst into the world's medical vocabulary as ... The public began to understand the crucial importance of ... infection and guarding against future attacks. , While scientists ... diseases, one area has remained murky: disorders caused by ...
... together, and most people find it impossible to tell ... just about everything, including their genes. But sometimes only ... both of them should. , Scientists at the University ... how two people who are so similar biologically can ...
Cached Biology News:New lab technique churns out fungus' potential cancer fighter 2Researchers add crucial information on how the body's T cells react to parasitic diseases 2Researchers add crucial information on how the body's T cells react to parasitic diseases 3How can identical twins be genetically different? 2How can identical twins be genetically different? 3
... personal-sized Thermal Cycler is the ideal instrument for ... range of PCR applications. Get Applied ... Save lab space without sacrificing results. ... Industry-Standard PCR Technology You Can Afford ...
... upgraded micro 10 represents a major advance ... of the benefits of large robotic liquid ... benchtop dispenser. Dispensing accurate volumes ranging from ... 10 has unique advantages not yet found ...
This free-standing laminar flow hood provides a horizontal flow of HEPA-filtered air to create a clean processing area. Air return slots along the front and side edges of the work area enhance system...
... Motic's B3 series of microscopes offer all ... required for laboratory work. Equipped with Koehler ... Contrast (ASC) objectives. The B3 is the ... Siedentopf binocular tube eliminates the need for ...
Biology Products: